New drug could keep lymphoma at bay in hepatitis b patients

NCT ID NCT07493109

Recruiting now Disease control Sponsor: Ou Bai, MD/PHD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing whether the drug chidamide can help prevent diffuse large B-cell lymphoma from returning in patients who also have hepatitis B. Participants must have achieved complete remission after initial chemotherapy (R-CHOP). They will take chidamide twice a week along with standard antiviral medication for hepatitis B. The study aims to see if this maintenance therapy improves how long patients stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Chidamide (also called Tucidinostat) and Entecavir
What this could lead to: If successful, this could provide a new maintenance treatment option to help keep lymphoma in remission longer for patients with hepatitis B.
What could go wrong: This is a Phase 3 trial, but it is still recruiting and results are not yet available. Chidamide may cause side effects, and the benefit over current monitoring alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)

Contacts and locations

Locations

The First Bethune Hospital of Jilin University
RECRUITING

Changchun, Jilin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.